


Angiotensin (1-7) (acetate)

| | |
|-----------------------------|---|
| Cat. No.: | HY-12403A |
| CAS No.: | 2855063-75-9 |
| Molecular Formula: | C ₄₃ H ₆₆ N ₁₂ O ₁₃ |
| Molecular Weight: | 959.06 |
| Sequence: | Asp-Arg-Val-Tyr-Ile-His-Pro |
| Sequence Shortening: | DRVYIHP |
| Target: | Angiotensin Receptor; Angiotensin-converting Enzyme (ACE); Endogenous Metabolite |
| Pathway: | GPCR/G Protein; Metabolic Enzyme/Protease |
| Storage: | Sealed storage, away from moisture Powder -80°C 2 years -20°C 1 year |

* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)



SOLVENT & SOLUBILITY

| | | | | | |
|---|---|--------------------------|--------------|-----------|------------|
| In Vitro | H ₂ O : 62.5 mg/mL (65.17 mM; Need ultrasonic) | | | | |
| | | Solvent Concentration | Mass 1 mg | 5 mg | 10 mg |
| | Preparing Stock Solutions | 1 mM | 1.0427 mL | 5.2134 mL | 10.4269 mL |
| | | 5 mM | 0.2085 mL | 1.0427 mL | 2.0854 mL |
| 10 mM | | 0.1043 mL | 0.5213 mL | 1.0427 mL | |
| Please refer to the solubility information to select the appropriate solvent. | | | | | |
| In Vivo | 1. Add each solvent one by one: PBS Solubility: 100 mg/mL (104.27 mM); Clear solution; Need ultrasonic | | | | |

BIOLOGICAL ACTIVITY

| | |
|-------------------------------------|---|
| Description | Angiotensin 1-7 (Ang-(1-7)) acetate is an endogenous heptapeptide from the renin-angiotensin system (RAS) with a cardioprotective role due to its anti-inflammatory and anti-fibrotic activities in cardiac cells. Angiotensin 1-7 acetate inhibits purified canine ACE activity (IC ₅₀ =0.65 μM). Angiotensin 1-7 acetate acts as a local synergistic modulator of kinin-induced vasodilation by inhibiting ACE and releasing nitric oxide. Angiotensin 1-7 acetate blocks Ang II-induced smooth muscle cell proliferation and hypertrophy and shows antiangiogenic and growth-inhibitory effects on the endothelium ^{[1][2][3]} . |
| IC₅₀ & Target | IC ₅₀ : 0.65 μM (ACE) ^[2] |
| In Vitro | Angiotensin 1-7 (Ang-(1-7)) inhibits cultured vascular smooth muscle cell growth, whereas equal molar concentration of Ang |

II stimulates cell growth^[2].

?Angiotensin 1-7 (Ang 1-7) abrogates the methylglyoxal-modified albumin (MGA)-stimulated myofibroblast phenotype by inhibiting the chronic stimulation of the TGF- β -ERK pathway in NRK-52E cells^[4].

?Angiotensin 1-7 signals through the Mas receptor (MasR) in opposition to Ang II/angiotensin II type 1 receptor (AT1R), promoting anti-inflammatory, vasodilatory, and neuroprotective effects^[5].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Daily Angiotensin 1-7 (Ang-(1-7)) treatment (0.01-0.06 mg/kg) results in significant amelioration of DSS-induced colitis.

Colitis-associated phosphorylation of p38, ERK1/2 and Akt is reduced by Ang 1-7 treatment^[3].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

CUSTOMER VALIDATION

- Chin Chem Lett. 2022 May 16.
- Cell Biosci. 2023 Feb 4;13(1):23.
- Biol Proced Online. 2022 Oct 25;24(1):15.
- Front Cell Dev Biol. 2021 Jun 11;9:659809.
- Int J Clin Exp Med. 2019;12(5):4773-4780.

See more customer validations on www.MedChemExpress.com

REFERENCES

[1]. Gómez-Mendoza DP, et al. Angiotensin-(1-7) oral treatment after experimental myocardial infarction leads to downregulation of CXCR4. J Proteomics. 2019;208:103486.

[2]. Li P, et al. Angiotensin-(1-7) augments bradykinin-induced vasodilation by competing with ACE and releasing nitric oxide. Hypertension. 1997 Jan;29(1 Pt 2):394-400.

[3]. Khajah MA, et al. Anti-Inflammatory Action of Angiotensin 1-7 in Experimental Colitis. PLoS One. 2016 Mar 10;11(3):e0150861.

[4]. Alzayadneh EM, et al. Angiotensin-(1-7) abolishes AGE-induced cellular hypertrophy and myofibroblast transformation via inhibition of ERK1/2. Cell Signal. 2014 Sep 19. pii: S0898-6568(14)00314-3.

[5]. Janatpour ZC, et al. Subcutaneous Administration of Angiotensin-(1-7) Improves Recovery after Traumatic Brain Injury in Mice. J Neurotrauma. 2019;36(22):3115-3131.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA